Eli Lilly and Company logo
LLYEli Lilly and Company
Trade LLY now
Eli Lilly and Company primary media

About Eli Lilly and Company

Eli Lilly (NYSE:LLY) is a global healthcare leader that specializes in creating high-quality medicines for multiple therapeutic areas. Engaging in comprehensive drug discovery to drive innovation, the company organizes its operations across human pharmaceutical products and animal health products divisions. Its projects primarily involve research, development, manufacturing and marketing operations. The company aims to offer successful medical breakthroughs, addressing severe health challenges, and assisting healthcare professionals in providing better treatments globally. Eli Lilly’s objectives include saving and improving lives, enhancing shareholder value through business growth and sustainability.

What is LLY known for?

Snapshot

Public US
Ownership
1876
Year founded
42001
Employees
Indianapolis, United States
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Indianapolis, US

Products and/or services of Eli Lilly and Company

  • Insulin Glargine injection, an advanced insulin therapy, stands as a milestone in a patient's disease management journey.
  • Taltz, a revolutionary plaque psoriasis treatment provides a beacon of hope for those seeking better skin health.
  • Cyramza, a targeted therapy for stomach and lung cancers.
  • Alimta, an innovative chemotherapy medicine for treating mesothelioma and non-small cell lung cancer.
  • Strattera, a non-stimulant medicine is a diverse treatment option for attention deficit hyperactivity disorder (ADHD).
  • Portrazza presents a major breakthrough in the treatment of metastatic squamous non-small cell lung cancer.

Eli Lilly and Company executive team

  • Mr. David A. RicksChairman & CEO
  • Mr. Lucas E. MontarceExecutive VP & CFO
  • Dr. Daniel M. Skovronsky M.D., Ph.D.Chief Scientific & Product Officer and President of Lilly Research Laboratories
  • Ms. Anat Hakim J.D.Executive VP, General Counsel & Secretary
  • Mr. Jacob S. Van NaardenExecutive VP & President of Lilly Oncology
  • Mr. Gordon BrooksGroup VP, Controller & Corporate Strategy
  • Mr. Donald A. ZakrowskiSenior VP of Finance & Chief Accounting Officer
  • Mr. Diogo RauExecutive VP and Chief Information & Digital Officer
  • Mr. Eric DozierExecutive VP & Chief People Officer
  • Mr. Jeffrey N. SimmonsSenior VP & President of Elanco Animal Health

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.